On Oct. 9, 2023, GlaxoSmithKline announced that it had reached an exclusive agreement with Chongqing Zhifei Biological Products to co-promote GSKﾒs shingles vaccine, Shingrix, in China for an initial three-year period, with the potential to extend the partnership should all parties agree.

Zhifei will purchase agreed volumes of Shingrix with a value to GSK of more than $3 billion in total over the initial three-year period.